The results are represented as fold change compared to expression levels in control siRNA treated cells (set to 1) and are representative of 2 donors for both mRNA and protein silencing (mean ± SD for PCR triplicates). Additionally, percentage silencing with respective doses of PPP1R11 siRNAs are represented as compared to respective dose of individual control siRNAs. Higher dose of PPP1R11 siRNA pool (2µM) increased silencing efficiency both in mRNA and protein level hence was chosen for further experiments. (C) Cells were transfected with 2 µM of indicated siRNAs for 4.5 days, or left untreated ("-", no transfection). Subsequently, cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 antibodies for 4.5 days and then stained with viability dye to determine viability by flow cytometry. Percentage of live cells (pre-gated on lymphocytes based on fsc/ssc and after doublet discrimination) is shown for n=4 donors (represented by individual symbols; lines and error bars represent mean ± SEM). P values were determined by paired t test. (D-F) De-convolution of the effect of different siRNAs for PPP1R11 silencing. T cells were treated with 2 µM of control siRNA, PPP1R11 siRNA pool (#06 -09) or individual PPP1R11 siRNAs (#06, 07, 08, 09 as indicated) for 4.5 days. T cells were further stimulated for 3 hours with TCR stimulation. PPP1R11 and IL2 mRNA levels were measured by qRT-PCR and normalized to RPL13A mRNA. In (D) and (F), the results are represented as fold change compared to expression levels in control siRNA treated cells (set to 1) and figures are representative of 2 donors each (mean ± SD of PCR triplicates). In (E), suppression assay involving Tregs and afore mentioned siRNA-treated T cells were conducted as described in Main Figure 2 . Individual silencing efficiencies with tested siRNAs were correlated with observed abrogation of IL2 mRNA suppression in respective cases (Pearson correlation coefficient = 0.99) (each siRNA represented by a different color).
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SUPPLEMENTAL FIGURE 2:
Effect of PPP1R11 silencing on activation-induced genes. T cells were treated with 2 µM of PPP1R11 siRNA pool or non-targeting (ct) siRNA for 4.5 days and then activated for 3 hours with soluble cross linked anti-CD3/CD28 antibodies at 37˚C. Respective mRNA levels measured by qRT-PCR were normalized to GAPDH mRNA and to expression levels in unstimulated cells treated with respected siRNAs. Averaged figures for respective mRNAs (mean ± SEM of 4 donors) are expressed as fold change PPP1R11 siRNA compared with control siRNA (Log2 set to 0). P values were determined by unpaired, one sample, twosided t test (*P < 0.05) . 
SUPPLEMENTAL FIGURE 3.
Studies on the mechanism of PPP1R11-induced cytokine expression in stimulated T cells. (A) T cells were treated with 2 μM of PPP1R11 siRNA pool or non-targeting siRNA for 4.5 days and activated for 4.5 days with plate-bound anti-CD3 and soluble anti-CD28 antibodies at 37˚C. CD3ε surface expression was analyzed by surface staining and flow cytometry. Median fluorescence intensity (MFI) for CD3ε is shown, pre-gated on lymphocytes (by fsc/ssc), single cells (by doublet discrimination), live cells (by viability dye) and CD3+CD4+ T cells. Mean ± SEM of 4 donors is shown and P value was determined by paired t test. (B) PPP1R11 silencing imparts an activated phenotype to T cells upon PMA/Ionomycin (PMA/Iono) stimulation. T cells were treated with 2 µM of PPP1R11 siRNA pool or non-targeting control siRNA for 4.5 days and activated for 3 hours with PMA/Iono stimulation. Respective cytokine mRNA levels measured by qRT-PCR were normalized to GAPDH mRNA and are represented as fold changes compared to expression levels in cells treated with control siRNA (set to 1). Representative expression for IL2 mRNA (left) and IFNG mRNA (right) (mean ± SD of PCR triplicates) for 2 donors is shown. (C) Western Blot analysis of canonical TCR signaling molecules in T cells treated with 2 µM of PPP1R11 siRNA pools or non-targeting siRNA for 4.5 days and then activated (i) for 4.5 days with plate-bound anti-CD3 and soluble anti-CD28 antibodies or (ii) for 30 minutes with PMA/Iono at 37˚C. Expression level of several proteins or phospho ("p-") proteins was determined by quantifying Western Blots and normalization to tubulin or corresponding total antibodies. For NFAT1, the ratio of NFAT1/p-NFAT1 was then determined. The normalized values are represented as fold change compared to expression level of the protein in unstimulated T cells (set to 1). The left panel shows blots from a representative donor, and the right panel shows quantification values for n=4 donors (mean ± SEM of 4 donors). P values were determined by paired, two-sided t test. represents the log2 of normalized gene count upon individual siRNA treatments (4.5 days) and, where indicated, subsequent TCR stimulation (6h) for 3 donors ("D1", "D2", "D3" = Donor 1, 2 ,3). The magnitude of normalized gene count is represented according to the indicated color scale. Only genes detected in all 3 donors and under all the conditions are included. Clustering indicates complete linkage Euclidian distance.
SUPPLEMENTAL FIGURE 5: Enrichment analyses of RNA-seq data. (A) Enrichment analysis report from comparative gene ontology (GO) analysis by Process Networks. GO analysis was performed with MetaCore software. Included in the analysis were differentially expressed genes upon PPP1R11 siRNA treatment with control siRNA treatment at 0h (P < 0.05). Top 50 process networks were represented from the Metacore analysis. (B) Enrichment analysis report from comparative gene ontology (GO) analysis by Pathway Maps. GO analysis was performed with MetaCore software. Included in the analysis were genes whose stimulation induced expression was differentially regulated by PPP1R11 siRNA treatment as compared to control siRNA treatment (referred as interaction term) (P < 0.05). Top 50 pathway maps were represented from the Metacore analysis.
Supplementary Table 3: Enrichment analysis report from comparative gene ontology (GO) analysis by Pathway Maps.
GO analysis was performed with MetaCore software. Included in the analysis were genes whose stimulation induced expression was differentially regulated by PPP1R11 siRNA treatment as compared to control siRNA treatment (also referred as interaction term) (P < 0.05) Top 50 pathway maps were represented from the Metacore analysis 
nucleoside transport 4 0,0002 0,4335 0,0002 0,4335 3 SLC29A2, ENT1, PMP34 2 regulation of cholesterol metabolic process 49 0,0002 0,4335 0,0002 0,4335 8 CYP51A1, SC5D, SCD, LMF1, PEX2, SREBP2 precursor, ARV1, DHCR7 3 regulation of steroid metabolic process 83 0,0005 0,4867 0,0005 0,4867 10 StARD4, CYP51A1, SC5D, SCD, LMF1, PEX2, SREBP2 precursor, ARV1, DHCR7, INSIG1 4 alcohol biosynthetic process 72 0,0007 0,4867 0,0007 0,4867 9 CYP51A1, SC5D, SC4MOL, HISPPD2A, IMPK, ARV1, DHCR7, INSIG1, DCoHM 5 cholesterol biosynthetic process 34 0,0009 0,4867 0,0009 0,4867 6 CYP51A1, SC5D, SC4MOL, ARV1, DHCR7, INSIG1 6 secondary alcohol biosynthetic process 35 0,0011 0,4867 0,0011 0,4867 6 CYP51A1, SC5D, SC4MOL, ARV1, DHCR7, INSIG1 7 uridine transport 2 0,0012 0,4867 0,0012 0,4867 2 SLC29A2, ENT1 8 positive regulation of cholesterol esterification 2 0,0012 0,4867 0,0012 0,4867 2 StARD4, SCD 9 pyrimidine nucleoside transport 2 0,0012 0,4867 0,0012 0,4867 2 SLC29A2, ENT1 10 sterol biosynthetic process 37 0,0015 0,5489 0,0015 0,5489 6 CYP51A1, SC5D, SC4MOL, ARV1, DHCR7, INSIG1 11 regulation of steroid biosynthetic process 67 0,0020 0,6219 0,0020 0,6219 8 StARD4, CYP51A1, SC5D, SCD, PEX2, SREBP2 precursor, DHCR7, INSIG1 12 lipid biosynthetic process 415 0,0022 0,6219 0,0022 0,6219 26 FATP, CYP51A1, Rab-5A, CERT, ADAS, PI3K class II (CII-alpha), SC5D, SC4MOL, coenzyme Q2 homolog, prenyltransferase (yeast), B3GNT5, CTE2, SGPP1, PLD6, DHRS7B, SCD, PI3K cat class IA (p110-beta), PEX2, DES1, SREBP2 precursor, ARV1, DHCR7, DCTN6, SMS1, INSIG1, PIPKI gamma, PI3K cat class IA (p110-alpha) 13 regulation of cholesterol biosynthetic process 41 0,0025 0,6219 0,0025 0,6219 6 CYP51A1, SC5D, SCD, PEX2, SREBP2 precursor, DHCR7 14 respiratory chain complex III assembly 9 0,0029 0,6219 0,0029 0,6219 3 SGA-81M, UQCRB, C11orf83 15 mitochondrial respiratory chain complex III assembly 9 0,0029 0,6219 0,0029 0,6219 3 SGA-81M, UQCRB, C11orf83 16 organic cyclic compound metabolic process 4032 0,0031 0,6219 0,0031 0,6219 164 FMT, Nibrin , StARD4, CYP51A1, FLJ13149, RPUSD4, 2'-PDE, Spindlin, SLC29A2, SRB7, ZNF800, TRIP11, ATRIP, CCBL2, METTL2A, MGA, PAF49, PIAS3, DCUP, ZN805, ZNF594, TARSL2, APLF, ENT1, UQCRQPC, MOCS3, SC5D, SC4MOL, NDPK  A, Twistnb, Axin2, SNFT, ZNF845, UXS1, Suv39H1, POP1 (RNase P/MRP subunit), CTE2, ZNF92, NDUFA8, MafK, CoREST, B3GALNT2, FANCD2, ZNF569, SFRS4, RNASEH2A, PLD6, CGI-09, METTL2B, DMAP1, GRINL1A, HSF2, WDR79, POLE3  (YBL1), JMJD2B, SMC3, SCML2, C17orf42, SCD, ClpX, ETR3, Geminin, DROSHA, UGDH, ZCCHC6, PAPD5, NSUN5B, BMS1 homolog, ZNF367, SURF5, GADD45 alpha, PAF1, ZNF529, PEX2, SMARCA3, ALAS1, ZNF619, BAZ1B, Pinin, MRM1, DUE-B, NDUFS4, NDUFC2, ATF-5, ZNF124, LARP7, CREST, C17orf85, UQCRB, ATP5E, CTR9, ZNF438, SREBP2 precursor, MYT1, KLF5, ZNF250, Gemin7, MJD (ataxin-3), c-Myb, ZNF669, MTF-1, SYHH, ARV1, ZNF264, MMAB, ZNF414, YCL1, DHCR7,  Securin, Cep290, SLC19A2, HYPA, SMC5, ZPR1, TAFII28, ZNF295, TCFbeta1, COMT, AP1S1A, SPBP, ZNF776, TRAP100, ELF1, C11orf83, NOC4L, CGI-99, KLF15, Hedls, DGCR14, BLAP75, Midasin, SLTM, TDRD3, Rcor2, CDC5L, HMG20A, TAF13,  COX VIIb-1, INSIG1, C1orf124, ZNF354C, DCoHM, RIOK3, WDR37, C20orf29, UBE2W, UTP6, PCGF3, Eftud1, ZNF827, CC2D1A, NCOA6 (TRBP), WDSOF1, APEX2, RBM10, ZNF573, ELF2, RBM13, YT521, COMMD3, ZNF48, CstF64, DDX41, ELL   17 protein quality control for misfolded or incompletely synthesized proteins 30 0,0032 0,6219 0,0032 0,6219 5 N-glycanase 1, MJD (ataxin-3), Klhl15, AP1S1A, UBE2W 18 organic hydroxy compound biosynthetic process 106 0,0034 0,6219 0,0034 0,6219 10 CYP51A1, SC5D, SC4MOL, PEX2, HISPPD2A, IMPK, ARV1, DHCR7, INSIG1, DCoHM 19 nucleoside transmembrane transport 3 0,0034 0,6219 0,0034 0,6219 2 SLC29A2, ENT1 20 regulation of cholesterol esterification 3 0,0034 0,6219 0,0034 0,6219 2 StARD4, SCD 21 mitochondrial fusion 19 0,0035 0,6219 0,0035 0,6219 4 AFG3L2, PLD6, BFL1, FAM73A 22 mitochondrial respiratory chain complex III biogenesis 10 0,0040 0,6684 0,0040 0,6684 3 SGA-81M, UQCRB, C11orf83 23 vasoconstriction 11 0,0054 0,6684 0,0054 0,6684 3 PI3K class II (CII-alpha), ARMET, BBS6 24 tRNA C5-cytosine methylation 4 0,0067 0,6684 0,0067 0,6684 2 METTL2A, METTL2B 25 cholesterol biosynthetic process via lathosterol 4 0,0067 0,6684 0,0067 0,6684 2 SC5D, DHCR7 26 cell proliferation in hindbrain 4 0,0067 0,6684 0,0067 0,6684 2 DSCR2, ATF-5 27 cholesterol esterification 4 0,0067 0,6684 0,0067 0,6684 2 StARD4, SCD 28 maltose metabolic process 4 0,0067 0,6684 0,0067 0,6684 2 GANC, MGAM 29 cholesterol biosynthetic process via desmosterol 4 0,0067 0,6684 0,0067 0,6684 2 SC5D, DHCR7 30 protein import into peroxisome matrix, docking 4 0,0067 0,6684 0,0067 0,6684 2 PEX13, PEX5R 31 steroid esterification 4 0,0067 0,6684 0,0067 0,6684 2 StARD4, SCD 32 sterol esterification 4 0,0067 0,6684 0,0067 0,6684 2 StARD4, SCD 33 cerebellar granule cell precursor proliferation 4 0,0067 0,6684 0,0067 0,6684 2 DSCR2, ATF-5 34 spindle assembly involved in meiosis 4 0,0067 0,6684 0,0067 0,6684 2 Emi1, Golgin-95 35 regulation of genetic imprinting 4 0,0067 0,6684 0,0067 0,6684 2 CTR9, PI3K cat class IA (p110-alpha) 36 cell proliferation in external granule layer 4 0,0067 0,6684 0,0067 0,6684 2 DSCR2, ATF-5 37 organic substance metabolic process 7009 0,0069 0,6684 0,0069 0,6684 263 FMT, Nibrin, StARD4, FATP, CYP51A1, FLJ13149, MRPL23, AFG3L2, RPUSD4, 2'-PDE, FBXW9, Rab-5A, Spindlin, SLC29A2, SRB7, ZNF800, CERT, TRIP11, ATRIP, CCBL2, METTL2A, UBE2H, MGA, ADAS, PAF49, PIAS3, DCUP, ZN805, ZNF594, TARSL2, APLF, Melanotransferrin, PI3K class II (CII-alpha), PDP2, RAB2A, ENT1, UQCRQPC, MOCS3, SLC7A6, ZDHHC23, FAM105B, SC5D, LYPLAL1, MRPS18C, ERO1Lalpha, SC4MOL, Rab12, Cullin 5, NDPK A, KIAA0143, Twistnb, N-glycanase 1, COQ10B, Axin2, FKBP15, coenzyme Q2 homolog, prenyltransferase (yeast), B3GNT5, VRK2, MOBKL1A, SNFT, ZNF845, UXS1, Suv39H1, FLJ10204, SIAE, MTIF2, NAGLU, POP1 (RNase P/MRP subunit), MLCP (reg), CTE2, ZNF92, NDUFA8, MafK, CoREST, B3GALNT2, FANCD2, SGPP1, ZNF569, COP1, SFRS4, RNASEH2A, p42 KKIALRE, PLD6, TMEM5, DHRS7B, CGI-09, DHRS3, GANC, FLJ11078, METTL2B, Synbindin, DMAP1, GRINL1A, HSF2, PEX13, WDR79, POLE3 (YBL1), JMJD2B, SMC3, SCML2, VCIP135, C17orf42, SCD, ClpX, ETR3, Geminin, LMF1, DROSHA, ERK3, UGDH, ZCCHC6, PAPD5, NSUN5B, BMS1 homolog, ZNF367, SURF5, UBXD7, GADD45 alpha, PAF1, LMTK2, PI3K cat class IA (p110-beta), ZNF529, KCTD5, PEX2, USP40, SMARCA3, HECTD1, HISPPD2A, ARTN, PPP1R3D, ALAS1, ZNF619, BAZ1B, Pinin, HECTD3, GGTA1 (A) Genes from RNA-seq data were classified into highly expressed genes (HEG) and lowly expressed genes (LEG) (left panel; cluster "1" and "2" respectively), based on the expression (Log 2 (normalized count)) mean of all samples. The cutoff for being classified HEG was determined to be 0.38 (Log 2 (normalized count)). (B) DEGs from Figure 4A ("unstim") and Figure 4B ("stim") were analyzed regarding their expression level, and the overlap with HEG and LEG class genes is shown in the Venn diagram (numbers represent number of genes). (C-E) T cells were treated with 2 µM of PPP1R11 siRNA pools or non-targeting siRNA for 4.5 days and then activated either with PMA/Ionomycin for 30 min or with TCR stimulation for 4.5 days at 37˚C. Expression level of several proteins, measured by quantifying Western Blots, were normalized to tubulin and are represented as fold change compared to expression level of the protein in unstimulated T cells (set to 1). 
